<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448680</url>
  </required_header>
  <id_info>
    <org_study_id>LFB-FVIIa-007-14</org_study_id>
    <nct_id>NCT02448680</nct_id>
  </id_info>
  <brief_title>A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa</brief_title>
  <acronym>PERSEPT2</acronym>
  <official_title>A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients From Birth to &lt;12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LFB USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LFB USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate
      dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the
      treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII
      or IX in 12 patients ( birth to &lt;6 years old), and 12 patients (≥6 years old to &lt;12 years
      old).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa
      (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to &lt;12 years old
      with Inhibitors to Factor VIII or IX: PerSept 2
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">August 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding episode treatment success</measure>
    <time_frame>12 hours after first administration of study drug</time_frame>
    <description>No additional hemostatic product required after 12 hours of first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to bleeding success</measure>
    <time_frame>12 hours</time_frame>
    <description>Patients shall rate the treatment of each bleeding episode. If treatment occurs under direct supervision of treating physician, the physician shall rate the response. Ratings based on a four point scale; Excellent, Good, Moderate, None</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>Pre-dose, 3 weeks post dose and then every 6 weeks until end of study</time_frame>
    <description>Based on Coagulation Factor VIIa (Recombinant), binding antibody levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic profile assessment</measure>
    <time_frame>Half of the patients sampling: at 10±2 minutes, 1 and 4 hours (±10 minutes), and the other half of the patients sampling: at 30±5 minutes and 2 and 8 hours (±10 minutes) relative to the start of infusion of study drug</time_frame>
    <description>Based on plasma concentrations of Coagulation Factor VIIa (Recombinant)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia A With Inhibitors</condition>
  <condition>Hemophilia B With Inhibitors</condition>
  <arm_group>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 75 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 µg/kg treatment regimen for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 225 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>225 µg/kg treatment regimen for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Coagulation FVIIa (Recombinant)</intervention_name>
    <description>A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX</description>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 75 µg/kg</arm_group_label>
    <arm_group_label>Coagulation Factor VIIa (Recombinant): 225 µg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be male with a diagnosis of congenital hemophilia A or B of any severity

          -  have one of the following:

          -  a positive inhibitor test BU ≥5, OR

          -  a Bethesda Unit (BU) &lt;5 but expected to have a high anamnestic response to FVIII or
             FIX, as demonstrated from the patient's medical history, precluding the use of factor
             VIII or IX products to treat bleeding episodes, OR

          -  a BU &lt;5 but expected to be refractory to increased dosing of FVIII or FIX, as
             demonstrated from the patient's medical history, precluding the use of factor VIII or
             IX products to treat bleeding episodes

          -  be aged from birth to &lt;12 years old

          -  have experienced at least 3 bleeding episodes of any severity in the past 6 months

          -  parents or legal guardians must be capable of understanding and be willing to comply
             with the conditions of the protocol

          -  parents or legal guardians must have read, understood, and provided written informed
             consent

        Exclusion Criteria:

          -  have any coagulation disorder other than hemophilia A or B

          -  be immunosuppressed (i.e., the patient may not be receiving systemic immunosuppressive
             medication; cluster of differentiation 4 (CD4) counts at screening must be &gt;200/µL)

          -  have a known allergy or hypersensitivity to rabbits

          -  have platelet count &lt;100,000/mL

          -  have had a major surgical procedure (e.g. orthopedic, abdominal) within 1 month prior
             to first administration of study drug

          -  have received an investigational drug within 30 days of first study drug
             administration, or be expected to receive such drug during participation in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meg Carini, LPN,BS</last_name>
    <phone>508-370-5258</phone>
    <email>meg.carini@lfb-usa.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffry Lawrence, MD</last_name>
    <phone>508-370-5113</phone>
    <email>jeff.lawrence@lfb-usa.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jimmy Everest Center for Cancer and Bleeding Disorders</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas / Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Winborn</last_name>
    </contact>
    <investigator>
      <last_name>Janna Journeycake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika Cepelakova</last_name>
      <phone>+420 (2) 2443 6537</phone>
      <email>veronika.cepelakova@fnmotol.cz</email>
    </contact>
    <investigator>
      <last_name>Vladimir Komrska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology of Department Hemophilia and Thromboses center</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamila Katselashvili</last_name>
    </contact>
    <investigator>
      <last_name>Tamila Nadiradze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Worthwhile Clinical Trials</name>
      <address>
        <city>Benoni</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadeela Bibi Rahman</last_name>
      <email>fadeela@wwct.co.za</email>
    </contact>
    <investigator>
      <last_name>Ismail Haroon Mitha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology (Ukraine)</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kateryna Vilchevska</last_name>
      <email>vilchevskaya@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Kateryna Vilchevska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandra Stasyshyn</last_name>
    </contact>
    <investigator>
      <last_name>Oleksandra Stasyshyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Georgia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

